Vigilant Biosciences Announces Three New Distribution Agreements for OncAlert™ Oral Cancer Product Line for Europe, Africa and Latin America

Vigilant Biosciences Announces Three New Distribution Agreements for OncAlert™ Oral Cancer Product Line for Europe, Africa and Latin America June 15, 2016 FORT LAUDERDALE, Florida Vigilant Biosciences, Inc. (“Vigilant”), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced three exclusive multi-year distribution agreements for sales

Vigilant Biosciences Announces Three New OncAlert Distribution Agreements for Europe, Africa, and Latin America

Vigilant Biosciences Announces Three New OncAlert Distribution Agreements for Europe, Africa, and Latin America June 15, 2016 The new OncAlert agreements will further expand Vigilant Biosciences’ reach and support the company’s goal to deliver accurate and cost-effective tools to aid clinicians in the diagnosis and treatment of oral cancer. Vigilant Biosciences Inc., an innovator and

From the Editor: Liquefaction, Dx Style

From the Editor: Liquefaction, Dx Style June 7, 2016 When technologies have matured to the point of market readiness, it can be hard to keep track of the many new products that suddenly become available to the marketplace. This spring, after many months of anticipation, early FDA approvals hint that the floodgates for so-called “liquid

Oral Rinse Test Picks Up Early-Stage Oral Cancer

Oral Rinse Test Picks Up Early-Stage Oral Cancer June 7, 2016 An inexpensive oral rinse test has been shown to distinguish head and neck cancer patients from people who are at high risk for the disease, and offers hope that the diagnosis of oral cancer could be made at a much earlier stage than it

Early Detection of Head and Neck Cancer Gets a Boost: Vigilant Biosciences Launches First-of-its-kind OncAlert Labs OraMark Test in the United States

Early Detection of Head and Neck Cancer Gets a Boost: Vigilant Biosciences Launches First-of-its-kind OncAlert Labs OraMark Test in the United States June 6, 2016 First quantitative laboratory-developed test to accurately measure a tumor-initiating and stem cell–associated biomarker for head and neck cancer in an oral rinse Vigilant Biosciences Inc. (Fort Lauderdale, Florida), a developer

© 2020 Vigilant Biosciences

Follow Us

3900001 Rev C